T
CLMT icon

Tahithromos’s Calumet Specialty Products CLMT Stock Holding History

Tahithromos’s Portfolio CLMT Stock Details CLMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-30,583
Closed -$973K – 38
2014
Q2 		$973K Sell
30,583
-46,931
-61% -$1.4M 0.23% 35
2014
Q1 		$2M Buy
+77,514
New +$2.12M 0.48% 32

Other funds holding CLMT

JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EAM
Edge Asset Management Seattle, Washington $13.2B AUM 19.52% 1-Year Est. Return
AAA
Adams Asset Advisors Dallas, Texas $882M AUM 42% 1-Year Est. Return
IMS
Index Management Solutions Philadelphia, Pennsylvania $101M AUM 12.09% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
CA
Corrado Advisors Ramsey, New Jersey $192M AUM 20.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return

Tahithromos's CLMT Position: Q3 2014 in Review

Tahithromos sold out of Calumet Specialty Products (CLMT) in Q3 2014, closing a stake of 30,583 shares — an estimated $973K sold.

Tahithromos first reported a position in CLMT in Q1 2014 and held it in 2 quarters. The position peaked at $2M in Q1 2014. 115 funds tracked by Wall St. Rank hold CLMT as of Q3 2014.

  • Tahithromos reported no remaining Calumet Specialty Products position as of Q3 2014 after selling out during the quarter.
  • Tahithromos sold 30,583 Calumet Specialty Products shares in Q3 2014, an estimated $973K.
  • Tahithromos first reported a position in Calumet Specialty Products in Q1 2014 and held it in 2 quarters.
  • Tahithromos's Calumet Specialty Products position peaked at $2M in Q1 2014.
  • 115 funds tracked by Wall St. Rank held Calumet Specialty Products as of Q3 2014.

Based on Tahithromos's 13F filing for Q3 2014, filed 24 Oct 2014.